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A role for endothelin in the pathogenesis of hypertension: Fact or
fiction? Endothelin-1 (ET-1) was discovered 10 years ago. Be-
cause it is one of the most potent vasoconstrictors in vivo, a
pathophysiological role for the peptide as a mediator of hyper-
tension has been postulated. Several clinical studies, however,
have been unable to identify elevated ET levels in the plasma of
hypertensive patients, suggesting that it does not play a prominent
role in this disease. More recently, evidence has been presented
that ETs act predominantly at the autocrine/paracrine level and
that measurements of plasma levels can give only an indirect view
of the activity of the system. In addition, transgenic technology has
uncovered new actions of the peptide systems in recent years,
which point to a key function of the system in prenatal develop-
ment. Moreover, investigation of conditions associated with hy-
pertensive end-organ damage, such as chronic renal failure, has
led to a re-evaluation of the role of the ET system in hypertension.
This article discusses this recent evidence and defines the exact
role of the ET system in hypertension and hypertensive end-organ
damage.
In the past decade, the role of the endothelial cells in the
regulation of vascular tone has become clear. Moncada et
al [1] described in 1976 the existence of prostacyclin in the
blood vessel wall, and in 1980, Furchgott and Zawadzki
reported that acetylcholine (Ach)-mediated vasodilation
depends on the presence of the endothelium [2], thus
showing that the endothelium regulates vascular smooth
muscle tone by elaborating potent endothelial-dependent
vasodilators. A vasoconstrictor role for the endothelium
has also been suggested. In 1985, Rubanyi and Vanhoutte
reported release by hypoxia of a diffusible vasoconstrictor
substance(s) from endothelial cells, independently of pros-
taglandin synthesis [3]. In 1988, Yanagisawa et al discov-
ered a 21-amino acid peptide, which was subsequently
named endothelin (ET), in the supernatant of cultured
porcine aortic endothelial cells [4]. In 1989, Miller et al
reported that systemic administration of synthetic ET re-
sulted in pronounced systemic, coronary, and renal vaso-
constriction in association with activation of the renin-
angiotensin-aldosterone system [5]. These investigators
postulated an important pathophysiological role for ET in
diseases such as congestive heart failure, hypertension,
atherosclerosis, and cerebrovascular disease. This review
focuses on the role of the ET system in hypertension and
hypertensive end-organ damage.
THE ENDOTHELIN SYSTEM
The ET family consists of three distinct 21-amino acid
peptides (ET-1, -2, and -3), all with very similar peptide
structure [4]. The genes encoding the different ETs have
been cloned and their regulation investigated [6–8]. ET-1,
the most important ET, is synthesized in both the endothe-
lium [4, 6] and vascular smooth muscle cells (VSMCs) [9].
Stimuli for ET-1 release are hypoxia, thrombin, angiotensin
II (Ang II), vasopressin, norepinephrine, bradykinin [4],
transforming growth factor-b1, and low shear stress [12];
high shear stress potently inhibits ET-1 secretion [13].
Besides the different ETs, two types of ET receptors occur
in the vasculature [14]: types A (ETA) and B (ETB). The
ETA receptor is highly selective for ET-1; the ETB receptor
is equally sensitive for all three ETs [16]. The ETA receptor
is present on VSMCs and mediates predominantly contrac-
tion by ET-1 [15]. The ETB receptor is present both on the
endothelium, where it releases nitric oxide and prostacy-
clin, thereby mediating relaxation, and also on VSMCs,
where it mediates vasoconstriction [17, 18]. ET-1 infusion
into the circulation produces transient vasodilation and
hypotension, followed by long-lasting, ETA-mediated vaso-
constriction and pressure increase. Besides the ability of
ETs to change vascular tone, they also induce hypertrophy
in smooth muscle cells and function as mitogens [19, 20].
Several mechanisms for ET involvement in the pathophys-
iology of hypertension are discussed here. Hypertension
could be mediated by high ET levels in the circulation or
the vascular wall or by alterations in response to ET at the
receptor level. A decrease in the response to the ETB
receptor, such as in the dysfunctional endothelium, might
attenuate the vasodilator response. Structural alterations of
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the vessel wall, such as an increase in wall thickness
(vascular hypertrophy due to ET’s mitogenic effects), could
play a role. Alternatively, ETs may elevate blood pressure
(BP) by causing renal sodium and water retention [21],
resulting in volume expansion. Finally, ET effects on the
central and peripheral nervous system can cause vasocon-
striction through the release of other substances [22].
ENDOTHELIN IN THE ETIOLOGY OF
HYPERTENSION
Prerequisites for proposing a role for ET in the patho-
physiology of hypertension are augmentation of the peptide
levels or potentiation of its vasoconstrictor response and
lowering of arterial BP in hypertensive diseases by reason-
ably selective ET antagonists. A causal relationship be-
tween ET and hypertension has been shown by the devel-
opment of a pressor response after infusing ET in animal
[23–26] and human [27] experiments. ET infusion tran-
siently lowers BP, followed by a prolonged rise. Viral
transfer of human preproET-1 cDNA into the rat liver
increases plasma ET levels sixfold and significantly in-
creases BP [28]. Similarly, the prerequisite for an important
role for ET in animal models of hypertension would be
increased ET levels in the vasculature or serum. However,
most hypertensive animal models investigated have normal
or only slightly increased plasma ET [29]. Only induction of
malignant hypertension, such as in the spontaneously hy-
pertensive rat (SHR) treated with desoxycorticosterone
acetate and salt [30] or in the two-kidney, one-clip (2K-1C)
hypertensive rat treated with caffeine, elevates plasma ET
levels significantly [31]. Under normal conditions, only
small amounts of ET-1 circulate. This may be due to rapid
removal of ET-1 from the circulation or preferential re-
lease toward the medial smooth muscle via a paracrine
mechanism. Approximately 80% of the total amount of
ET-1 synthesized by endothelial cells is found on the
abluminal side [32], implying that circulating levels of ET-1
do not reflect true local concentrations in blood vessel walls
and that ET-1 is primarily a locally acting, rather than a
circulating, hormone [33]. Among animal models of hyper-
tension, only the desoxycorticosterone acetate (DOCA)-
salt rat and the DOCA-salt SHR have increased ET-1
mRNA levels in vessel walls. Surprisingly, SHR have
similar or lower ET-1 mRNA than normotensive controls
[34]. In 2K-1C hypertensive rats, however, blood vessel wall
ET-1 mRNA is slightly elevated [35], and in Dahl rats, the
ET-3 locus cosegregates with BP [36]. In the hypertensive
models, elevated vessel ET-mRNA may mediate important
structural effects, such as vascular hypertrophy, due to its
growth-promoting properties [19, 37]. Interestingly,
DOCA-salt hypertensive rat arteries show severe vascular
hypertrophy with prominent medial thickening [38] and
overexpression of the ET-1 gene [34]. In contrast, little
vascular hypertrophy and no ET-1 gene expression are seen
in SHR [39]. Additional information has been provided by
experiments on the effect of ET inhibitors on BP in
hypertensive models. In the DOCA-salt hypertensive rat,
ET antagonists lower BP and almost normalize vascular
hypertrophy [34]. ET antagonists also lower BP in the
DOCA-salt treated SHR with malignant hypertension [40]
and in the stroke-prone SHR [41]. In Dahl-salt hyperten-
sive rats, ET blockade decreases but does not normalize BP
[42]. In contrast, in the 2K-1C or 1K-1C hypertensive rat
[35] and in SHR [43], ET antagonists do not lower BP or
affect vascular hypertrophy. This discrepancy may reflect
strain-specific mechanisms in the pathogenesis of hyperten-
sion. Whether an ET antagonist influences BP possibly
depends on the relative importance of the ET system in the
specific hypertensive model (Table 1).
In conclusion, it seems that in the DOCA-salt hyperten-
sive rat and in rats with malignant hypertension, ET plays a
more important role than in other models; that is, not all
animal hypertensive models are the same. The different
hypertensive diseases probably have different etiologies in
which ET plays different roles, but in more severe forms of
hypertension, such as malignant and in the stroke-prone
SHR, ET plays a clear central role.
ENDOTHELIN IN HUMAN HYPERTENSION
In humans with mild to moderate hypertension, plasma
ET-1 levels are normal or only slightly increased [44, 45].
End-organ damage, however, appears to be a confounding
factor because hypertensive patients with renal disease
have higher plasma ET levels than those without renal
Table 1. Endothelin expression in rat models of hypertension
Strain or model Vascular ET-1 mRNA Plasma ET ET inhibition
DOCA-salt High [34] Normal [29] Lower BP [34]
2K, 1C/1K, 1C Slightly elevated [35] Normal No effect [35]
2K, 1C 1 caffeine Not known Elevated [31] Not known
SHR Normal or low [34] Normal [29] No effect [43]
SHRsp Not known Not known Lower BP [41]
SHR 1 DOCA/salt High [34] Elevated [30] Lower BP [40]
Dahl Not known Not known Slightly lower BP [42]
Abbreviations are: BP, blood pressure; DOCA, desoxycorticosterone acetate; 2(1)K, 1C two (one)-kidney-one clip; SHR, spontaneously hypertensive
rat; SHRsp, stroke-prone SHR.
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involvement [46]. Similarly, ET levels are higher in salt-
sensitive essential hypertension [47] and in obese hyperten-
sives [48] than in normotensive controls. Racial differences
for ET levels in human hypertension have also been
suggested. Thus, plasma immunoreactive ET-1 levels are
significantly higher in Black than in White hypertensives
[49]. Furthermore, the severity of hypertension correlates
with plasma ET levels [46, 50], and in malignant hyperten-
sion, plasma ET-1 levels are extremely high [51, 52]. In
addition, Schiffrin et al have shown increased vascular ET-1
expression in patients with severe hypertension [53]. An-
other form of hypertension in which ETs play a major role
is that seen in a small group of patients with hemangioen-
dothelioma. These patients have elevated BP and increased
plasma ET-1. Surgery reduces BP and plasma ET-1, and
after tumor relapse, BP and ET-1 increase again [54]. ET-1
gene expression has been detected also in human pheo-
chromocytoma [55], and also plasma ET-1 levels are signif-
icantly higher in such patients than in patients with essen-
tial hypertension or normal subjects [56]. Another
hypertensive disease reportedly accompanied by elevated
ET-1 levels is pre-eclampsia or eclampsia [57, 58], with
even higher levels in patients with severe pregnancy-in-
duced hypertension [58] or the hypertension, elevated liver
enzymes, and low platelet count (HELLP) syndrome [59].
In contrast, plasma ET-1 and big ET-1 are not elevated in
pregnant women with chronic hypertension [60]. Not only
are different hypertensive diseases associated with elevated
plasma ET levels, but several substances, such as cyclospor-
ine and erythropoietin, can also increase ET plasma. In
patients receiving cyclosporine after heart, liver, or kidney
transplantation, plasma ET-1 concentration is elevated [61,
62]. Because cyclosporines induce hypertension, ET may
play an important role in the etiology of this hypertension.
Administration of human recombinant erythropoietin to
patients with chronic renal failure on hemodialysis may be
associated with increased plasma levels of ET-1, which, in
turn, could contribute to the hypertension seen in these
patients (Table 2) [63]. Although there are no studies
concerning ET antagonists and BP in humans, experiments
on ETA receptor antagonists in the human forearm circu-
lation [64] and skin microcirculation [65] suggest that ETs
contribute to basal vascular tone. The role for ET in human
hypertension thus appears similar as in animal models: a
more important pathophysiological role in the more severe
forms or in hypertension with end-organ damage.
ENDOTHELIN AND HYPERTENSIVE END-ORGAN
DAMAGE
Based on the evidence presented earlier here, ET could
play an important role in end-organ damage in hyperten-
sive diseases. Chronic hypertension is commonly character-
ized by three types of end-organ damage: renal failure,
heart failure, and vascular disease.
Renal failure
Endothelin is important in the kidney. ET infusion
reduces renal blood flow (RBF), glomerular filtration rate
(GFR), and sodium excretion [24, 66]. Intravenous infusion
of anti-ET-1/3 antibodies into rat kidney increases RBF,
suggesting ET involvement in the physiological control of
renovascular tone [67]. Infusion of anti-ET antibodies has a
renal protective effect in ischemia [68] and in cyclosporine
nephrotoxicity [69]. In a further study, ET-1 infusion in
humans participates in volume homeostasis, where patho-
physiological concentrations contributed to renal vasocon-
striction and sodium retention: These could be prevented
by a Ca2 channel antagonist that blocks the elevation of
intracellular [Ca21] or prevents the direct opening of ion
channels [70, 71]. Similarly, infusion of an ET antagonist
into the renal interstitium in SHR improves renal hemody-
namics and excretory function [72]. As mentioned earlier
here, hypertensive diseases with renal involvement have
elevated ET levels, so it may be clear that the renal ET
system may play an important role in the dynamic regula-
tion of renal flow not only in normal physiology but also in
chronic hypertension.
Heart failure
Endothelin infusion increases coronary vascular resis-
tance and decreases cardiac output and heart rate [24, 73].
After transfection with the preproET-1 gene, contraction
of porcine arteries in vivo is augmented due to increased
sensitivity to Ang I, implying a role for ET-1 in the
pathogenesis of cardiovascular disease [74]. Increased ET
levels are reported in heart failure, an important constitu-
ent of hypertensive end-organ damage, suggesting a possi-
ble role for ET in this disease [75]. In this context, mortality
decreases and cardiac function improves after treatment of
rats with chronic heart failure with the ETA inhibitor
BQ-123. These benefits are accompanied by significant
amelioration of left ventricular dysfunction and prevention
Table 2. Endothelin (ET) plasma levels in human hypertensive disease
Disease Plasma ET-1
Correlation with
hypertension
Essential hypertension Normal/slightly
elevated [44, 45]
Low
Essential hypertension with
salt sensitivity/renal
involvement
Elevated [46, 47] High
Essential hypertension in
obese/black patients
Elevated [48, 49] Intermediate
Malignant hypertension High [51, 52] High
Pheochromocytoma Elevated [55, 56] Difficult to
interpret
Hemangioendothelioma High [54] High
Preeclampsia/eclampsia Elevated [57, 58] High
HELLP syndrome High [59] High
Cyclosporine hypertension Elevated [61, 62] High
Erythropoeitin hypertension Normal/elevated [63] Difficult to
interpret
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of ventricular remodeling, in which there is usually an
increase in the ventricular mass and ventricular cavity
enlargement [76]. ET-1 increases after cardiac infarction in
rats, and pretreatment with an anti-ET-g-globulin in this
model reduces infarct size by up to 40% [77]. In addition,
infusion of ETA receptor antagonists reduces infarct size in
animals when infused before the ischemic event [78].
Myocardial infarction increases plasma ET not only in
animals, but also in patients [79], and ET levels are lower in
patients with early coronary artery reperfusion than in
patients without early reperfusion. Plasma ET levels also
may predict hemodynamic complications in patients with
myocardial infarction [80], as plasma ET levels apparently
correlate with highest creatinine phosphokinase (CPK),
CPK-MB-isoenzyme levels, and low ejection fraction [81].
Accordingly, serum ET levels may be a prognostic indicator
of survival after acute myocardial infarction.
Vascular disease
In all rat hypertension models, impaired endothelium-
dependent relaxation occurs in large conduit arteries like
the aorta [82]. Two independent groups have reported
impaired endothelium-dependent vasodilation to Ach with
preserved, or only slightly altered, responsiveness to so-
dium nitroprusside in the forearm circulation of patients
with essential hypertension [83, 84]. In some hypertensive
diseases, increased ET-1 levels accompany elevated von
Willebrand factor, indicating general endothelial damage
[47, 85]. ET-1 levels are markedly raised in diseases with
diffuse endothelial dysfunction, such as diseases with hy-
pertension, atheroscleroses, renal insufficiency, congestive
heart failure [86, 87], and eclampsia or the HELLP syn-
drome [58, 59]. Although high ET levels are often viewed as
a marker of endothelial damage, ET may itself cause
endothelial dysfunction. We found recently that high ET-2
levels cause endothelial dysfunction in the ET-2 transgenic
rat. This rat has a 2.5-fold increase in serum ET-2, a level
comparable to that in pathophysiological conditions. In
these animals endothelium-dependent Ach-mediated relax-
ation is attenuated [88]. These data show that ET is not
only a marker for endothelial dysfunction, but that it may
also impair endothelial function. High ET levels occur also
in atherosclerosis [86], and in vivo ET has served as a
chemotactic agent for monocytes and also stimulates mi-
gration and proliferation of VSMCs, thereby sustaining the
atherosclerotic process [7, 89]. As described earlier here,
ischemia, a complication of atherosclerotic vascular dis-
ease, further stimulates both the release of ET and exter-
nalization of ET binding sites [90, 91]. This indirect evi-
dence (which obviously awaits the results of trials with a
specific antagonist) strongly implies participation of ET in
complications of the hypertensive process.
In all forms of hypertensive end-organ damage, ET is
elevated, and in heart failure, there could even be an
important role for ET antagonists. Not only does ET play a
central role in the physiology of the different organs
involved in end-organ damage but also in severe pathology
caused by hypertension. In summary, we propose that when
hypertension progresses and organ damage develops, ET
has a central role in this process, irrespective of the initial
hypertensive etiology.
CONCLUSION
Obviously, a causal relationship between ET and hyper-
tension is difficult to prove. Not all hypertensive conditions
have elevated ET levels, but it is highly conceivable that
hypertension is a heterogeneous disease entity. ET is
clearly more relevant in some hypertensive disorders. ET is
elevated in all severe forms of hypertensive diseases, espe-
cially those with end-organ damage. ET is elevated in rats
and humans with malignant hypertension, in humans with
essential hypertension with renal involvement, and in pa-
tients with the HELLP syndrome. It remains to be estab-
lished whether the increase in circulating ET-1 is involved
in the development of the disease state or is a secondary
phenomenon due to activation of the ET system at the
cellular level.
One explanation proposes a vicious cycle in which end-
organ damage and ET levels mutually reinforce each other.
ET has substantial effects in the renal circulation—reduc-
ing GFR and RBF—which, in turn, may increase renin
activity [24]. Furthermore, already only minor elevations in
ET concentrations potentiate effects of other vasoconstric-
tors, such as norepinephrine, Ang II, and serotonin. Stim-
ulation of perfused mesenteric arteries by Ang II is associ-
ated with endothelium-dependent potentiation of the
response to norepinephrine. As this response is prevented
both by phosphoramidone, an ET-converting enzyme in-
hibitor, and an anti-ET antibody, this strongly suggests that
Ang II can stimulate local vascular ET production, which in
turn, augments contractile responses to norepinephrine. If
this occurs in vivo, such responses may participate in the
pressure effects of very low concentrations of Ang II [92].
ET may, moreover, contribute to the hemodynamic effects
of Ang II in both SHR and normotensive control rats and
may contribute to the exaggerated pressor responsiveness
of the SHR to Ang II [93]. This potentiation of vasocon-
striction may lead in patients to hypertension without
elevation of plasma ET. Angiotensin-converting enzyme
inhibitors and Ang II receptor antagonists accordingly
prevent the pressor response to ET [94]. ET levels could
then rise, due to stimulation by Ang II or to endothelial
damage by hypertension itself or due to the damaging
effects of ET. The elevated ET concentration then elicits
further vasoconstriction and worsening of hypertension,
acting together with an enhanced renin-angiotensin system
in a vicious circle worsening hypertension.
A further possible mechanism for ET in the etiology or
attenuation of hypertension lies in the induction of vascular
hypertrophy by ET, which can worsen hypertension. This
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hypothesis also explains why ET levels are not elevated in
all hypertensive diseases. Another reason for low ET levels
in some hypertensive diseases is that endothelial ET-1
secretion is mostly abluminal so that circulating ET-1
concentrations may not reflect vascular production. Only
when malignant hypertension is induced in SHR by
DOCA-salt treatment is the ET-1 gene overexpressed in
the blood vessels [30]. It is possible, but as yet unproven,
that the proportion of hypertensive patients showing en-
hanced expression of ET-1 in blood vessel walls will
increase if severe forms of hypertension are investigated,
because it is essentially in the more severe or malignant
forms of hypertension that are accompanied by increases in
plasma ET [51, 52]. In conclusion, in severe hypertension
with end-organ damage, a causal role for ET is very likely.
Its pathophysiological role in milder forms of hypertension
and in the absence of hypertension is more questionable.
APPENDIX
Abbreviations used in this article are: Ach, acetylcholine; Ang II,
angiotensin II; BP, blood pressure; CPK, creatinine phosphokinase;
DOCA, desoxycorticosterone acetate; ET, endothelin; GFR, glomerular
filtration rate; HELLP, hypertension, elevated liver enzymes, and low
platelet count; RBF, renal blood flow; SHR, spontaneously hypertensive
rat; VSMCs, vascular smooth muscle cells.
Reprint requests to Martin Paul, M.D., P/A Freie Universita¨t Berlin,
Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin
Medical Center, Hindenburgdamm 30, D-12200 Berlin, Germany.
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